BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

646 related articles for article (PubMed ID: 33841395)

  • 1. Severe Acute Respiratory Syndrome Coronavirus 2 Spike Protein Based Novel Epitopes Induce Potent Immune Responses
    Vishwakarma P; Yadav N; Rizvi ZA; Khan NA; Chiranjivi AK; Mani S; Bansal M; Dwivedi P; Shrivastava T; Kumar R; Awasthi A; Ahmed S; Samal S
    Front Immunol; 2021; 12():613045. PubMed ID: 33841395
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comprehensive characterization of the antibody responses to SARS-CoV-2 Spike protein finds additional vaccine-induced epitopes beyond those for mild infection.
    Garrett ME; Galloway JG; Wolf C; Logue JK; Franko N; Chu HY; Matsen FA; Overbaugh JM
    Elife; 2022 Jan; 11():. PubMed ID: 35072628
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An Engineered Receptor-Binding Domain Improves the Immunogenicity of Multivalent SARS-CoV-2 Vaccines.
    Guo Y; He W; Mou H; Zhang L; Chang J; Peng S; Ojha A; Tavora R; Parcells MS; Luo G; Li W; Zhong G; Choe H; Farzan M; Quinlan BD
    mBio; 2021 May; 12(3):. PubMed ID: 33975938
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity.
    Yang J; Wang W; Chen Z; Lu S; Yang F; Bi Z; Bao L; Mo F; Li X; Huang Y; Hong W; Yang Y; Zhao Y; Ye F; Lin S; Deng W; Chen H; Lei H; Zhang Z; Luo M; Gao H; Zheng Y; Gong Y; Jiang X; Xu Y; Lv Q; Li D; Wang M; Li F; Wang S; Wang G; Yu P; Qu Y; Yang L; Deng H; Tong A; Li J; Wang Z; Yang J; Shen G; Zhao Z; Li Y; Luo J; Liu H; Yu W; Yang M; Xu J; Wang J; Li H; Wang H; Kuang D; Lin P; Hu Z; Guo W; Cheng W; He Y; Song X; Chen C; Xue Z; Yao S; Chen L; Ma X; Chen S; Gou M; Huang W; Wang Y; Fan C; Tian Z; Shi M; Wang FS; Dai L; Wu M; Li G; Wang G; Peng Y; Qian Z; Huang C; Lau JY; Yang Z; Wei Y; Cen X; Peng X; Qin C; Zhang K; Lu G; Wei X
    Nature; 2020 Oct; 586(7830):572-577. PubMed ID: 32726802
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Elucidation of cellular targets and exploitation of the receptor-binding domain of SARS-CoV-2 for vaccine and monoclonal antibody synthesis.
    Baig AM; Khaleeq A; Syeda H
    J Med Virol; 2020 Nov; 92(11):2792-2803. PubMed ID: 32573788
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Static all-atom energetic mappings of the SARS-Cov-2 spike protein and dynamic stability analysis of "Up" versus "Down" protomer states.
    Peters MH; Bastidas O; Kokron DS; Henze CE
    PLoS One; 2020; 15(11):e0241168. PubMed ID: 33170884
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Microneedle array delivered recombinant coronavirus vaccines: Immunogenicity and rapid translational development.
    Kim E; Erdos G; Huang S; Kenniston TW; Balmert SC; Carey CD; Raj VS; Epperly MW; Klimstra WB; Haagmans BL; Korkmaz E; Falo LD; Gambotto A
    EBioMedicine; 2020 May; 55():102743. PubMed ID: 32249203
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Importance of Neutralizing Monoclonal Antibodies Targeting Multiple Antigenic Sites on the Middle East Respiratory Syndrome Coronavirus Spike Glycoprotein To Avoid Neutralization Escape.
    Wang L; Shi W; Chappell JD; Joyce MG; Zhang Y; Kanekiyo M; Becker MM; van Doremalen N; Fischer R; Wang N; Corbett KS; Choe M; Mason RD; Van Galen JG; Zhou T; Saunders KO; Tatti KM; Haynes LM; Kwong PD; Modjarrad K; Kong WP; McLellan JS; Denison MR; Munster VJ; Mascola JR; Graham BS
    J Virol; 2018 May; 92(10):. PubMed ID: 29514901
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Avian antibodies (IgY) targeting spike glycoprotein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) inhibit receptor binding and viral replication.
    Artman C; Brumfield KD; Khanna S; Goepp J
    PLoS One; 2021; 16(5):e0252399. PubMed ID: 34048457
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibody signature induced by SARS-CoV-2 spike protein immunogens in rabbits.
    Ravichandran S; Coyle EM; Klenow L; Tang J; Grubbs G; Liu S; Wang T; Golding H; Khurana S
    Sci Transl Med; 2020 Jul; 12(550):. PubMed ID: 32513867
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rapid Development of SARS-CoV-2 Spike Protein Receptor-Binding Domain Self-Assembled Nanoparticle Vaccine Candidates.
    Kang YF; Sun C; Zhuang Z; Yuan RY; Zheng Q; Li JP; Zhou PP; Chen XC; Liu Z; Zhang X; Yu XH; Kong XW; Zhu QY; Zhong Q; Xu M; Zhong NS; Zeng YX; Feng GK; Ke C; Zhao JC; Zeng MS
    ACS Nano; 2021 Feb; 15(2):2738-2752. PubMed ID: 33464829
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neutralizing Monoclonal Antibodies Inhibit SARS-CoV-2 Infection through Blocking Membrane Fusion.
    Li CJ; Chao TL; Chang TY; Hsiao CC; Lu DC; Chiang YW; Lai GC; Tsai YM; Fang JT; Ieong S; Wang JT; Chang SY; Chang SC
    Microbiol Spectr; 2022 Apr; 10(2):e0181421. PubMed ID: 35293796
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of the Receptor-Binding Domain of the Spike Glycoprotein of Human Betacoronavirus HKU1.
    Qian Z; Ou X; Góes LG; Osborne C; Castano A; Holmes KV; Dominguez SR
    J Virol; 2015 Sep; 89(17):8816-27. PubMed ID: 26085157
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhanced Binding of SARS-CoV-2 Spike Protein to Receptor by Distal Polybasic Cleavage Sites.
    Qiao B; Olvera de la Cruz M
    ACS Nano; 2020 Aug; 14(8):10616-10623. PubMed ID: 32806067
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimized Pseudotyping Conditions for the SARS-COV-2 Spike Glycoprotein.
    Johnson MC; Lyddon TD; Suarez R; Salcedo B; LePique M; Graham M; Ricana C; Robinson C; Ritter DG
    J Virol; 2020 Oct; 94(21):. PubMed ID: 32788194
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nanoparticle Vaccines Based on the Receptor Binding Domain (RBD) and Heptad Repeat (HR) of SARS-CoV-2 Elicit Robust Protective Immune Responses.
    Ma X; Zou F; Yu F; Li R; Yuan Y; Zhang Y; Zhang X; Deng J; Chen T; Song Z; Qiao Y; Zhan Y; Liu J; Zhang J; Zhang X; Peng Z; Li Y; Lin Y; Liang L; Wang G; Chen Y; Chen Q; Pan T; He X; Zhang H
    Immunity; 2020 Dec; 53(6):1315-1330.e9. PubMed ID: 33275896
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Simplified SARS-CoV-2 Mouse Model Demonstrates Protection by an Oral Replicon-Based mRNA Vaccine.
    Jawalagatti V; Kirthika P; Hewawaduge C; Park JY; Yang MS; Oh B; So MY; Kim B; Lee JH
    Front Immunol; 2022; 13():811802. PubMed ID: 35250985
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neutralization of SARS-CoV-2 requires antibodies against conformational receptor-binding domain epitopes.
    Gattinger P; Niespodziana K; Stiasny K; Sahanic S; Tulaeva I; Borochova K; Dorofeeva Y; Schlederer T; Sonnweber T; Hofer G; Kiss R; Kratzer B; Trapin D; Tauber PA; Rottal A; Körmöczi U; Feichter M; Weber M; Focke-Tejkl M; Löffler-Ragg J; Mühl B; Kropfmüller A; Keller W; Stolz F; Henning R; Tancevski I; Puchhammer-Stöckl E; Pickl WF; Valenta R
    Allergy; 2022 Jan; 77(1):230-242. PubMed ID: 34453317
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recombinant Receptor-Binding Domains of Multiple Middle East Respiratory Syndrome Coronaviruses (MERS-CoVs) Induce Cross-Neutralizing Antibodies against Divergent Human and Camel MERS-CoVs and Antibody Escape Mutants.
    Tai W; Wang Y; Fett CA; Zhao G; Li F; Perlman S; Jiang S; Zhou Y; Du L
    J Virol; 2017 Jan; 91(1):. PubMed ID: 27795425
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Natural and Recombinant SARS-CoV-2 Isolates Rapidly Evolve
    Shiliaev N; Lukash T; Palchevska O; Crossman DK; Green TJ; Crowley MR; Frolova EI; Frolov I
    J Virol; 2021 Oct; 95(21):e0135721. PubMed ID: 34406867
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.